Fulstan (falecalcitriol) / Kissei, Sumitomo Pharma, Taisho - LARVOL DELTA

Recent Advancements Towards the Use of Vitamin D Isoforms and the Development of Their Synthetic Analogues as New Therapeutics. (PubMed, Biomedicines) - "Several analogues, such as alfacalcidol, paricalcitol, and falecalcitriol, are used for managing CKD-related bone disorders, while eldecalcitol is effective for osteoporosis, and calcipotriol against psoriasis. Advanced analytical techniques such as LC/ESI-MS/MS facilitate precise detection of vitamin D metabolites, further improving pharmacokinetic profiling. Future research may enable the clinical approval of novel vitamin D-based therapeutics with minimal disruption to calcium-phosphorus balance."

Journal • Review • Asthma • Dermatology • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Oncology • Osteoporosis • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • EGFR • KRAS

CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company | N=45 ➔ 60

Enrollment change • Endocrine Disorders • CASR

CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - P3 | N=45 | Recruiting | Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company

New P3 trial • Endocrine Disorders • CASR

Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor. (PubMed, J Pharm Biomed Anal) - "Therefore, the induction of FGF23 in osteocytes by vitamin D may be primarily mediated via VDR. The potential of 25(OH)vitamin D, paricalcitol, and maxacalcitol to induce FGF23 production was almost the same as that of 1α,25-dihydroxyvitamin D. However, falecalcitriol and eldecalcitol demonstrated a reduced potential to induce FGF23 compared with 1α,25-dihydroxyvitamin D. Our results demonstrate that FGF23 induction is different among the analogs of 1α,25-dihydroxyvitamin D. Therefore, an appropriate vitamin D analog should be chosen for each patient with mineral and bone disorder, considering its effect on FGF23 production."

Journal • FGF23